{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:12:01Z","timestamp":1755036721895,"version":"3.38.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":700,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1124\/molpharm.122.000583","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T22:40:11Z","timestamp":1668033611000},"page":"89-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human \u03b21-Adrenoceptor"],"prefix":"10.1016","volume":"103","author":[{"given":"Victor Jun Yu","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.W.","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian G.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.122.000583_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","article-title":"The selectivity of \u03b2-adrenoceptor antagonists at the human \u03b21, \u03b22 and \u03b23 adrenoceptors","volume":"144","author":"Baker","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1124\/molpharm.122.000583_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1476-5381.2010.00754.x","article-title":"The selectivity of \u03b2-adrenoceptor agonists at the human \u03b21, \u03b22 and \u03b23 adrenoceptors","volume":"160","author":"Baker","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/molpharm.122.000583_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/acsptsci.0c00051","article-title":"Using esterase selectivity to determine the in vivo duration of systemic availability and abolish systemic side-effects of topical \u03b2-blockers","volume":"3","author":"Baker","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1124\/molpharm.122.000583_bib4","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1096\/fj.201601305R","article-title":"Novel selective \u03b21-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease","volume":"31","author":"Baker","year":"2017","journal-title":"FASEB J"},{"key":"10.1124\/molpharm.122.000583_bib5","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1096\/fj.11-192435","article-title":"Predicting in vivo cardiovascular properties of \u03b2-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses","volume":"25","author":"Baker","year":"2011","journal-title":"FASEB J"},{"key":"10.1124\/molpharm.122.000583_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/mol.114.091587","article-title":"Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human \u03b21-adrenoceptor","volume":"85","author":"Baker","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.122.000583_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1124\/mol.114.095364","article-title":"Salmeterol\u2019s extreme \u03b22 selectivity is due to residues in both extracellular loops and transmembrane domains","volume":"87","author":"Baker","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.122.000583_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/thoraxjnl-2016-208412","article-title":"\u03b2-blockers, heart disease and COPD: current controversies and uncertainties","volume":"72","author":"Baker","year":"2017","journal-title":"Thorax"},{"key":"10.1124\/molpharm.122.000583_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1476-5381.1965.tb01782.x","article-title":"Comparison of some properties of pronethalol and propranolol","volume":"25","author":"Black","year":"1965","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1124\/molpharm.122.000583_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1126\/science.1150577","article-title":"High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor","volume":"318","author":"Cherezov","year":"2007","journal-title":"Science"},{"key":"10.1124\/molpharm.122.000583_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1124\/molpharm.122.000583_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0165-6147(97)01138-3","article-title":"The elusive nature of intrinsic efficacy","volume":"19","author":"Clarke","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/molpharm.122.000583_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijcard.2007.01.069","article-title":"Are we misunderstanding beta-blockers","volume":"120","author":"Cruickshank","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1124\/molpharm.122.000583_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1124\/molpharm.122.000583_bib15","doi-asserted-by":"crossref","first-page":"9494","DOI":"10.1073\/pnas.85.24.9494","article-title":"Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1\/beta 2-adrenergic receptors","volume":"85","author":"Frielle","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.122.000583_bib16","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1021\/ct9000685","article-title":"ACEMD: accelerating biomolecular dynamics in the microsecond time scale","volume":"5","author":"Harvey","year":"2009","journal-title":"J Chem Theory Comput"},{"key":"10.1124\/molpharm.122.000583_bib17","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0026-895X(24)12763-0","article-title":"Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists","volume":"56","author":"Isogaya","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.122.000583_bib18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/acs.jctc.8b01066","article-title":"CHARMM-GUI Membrane Builder for complex biological membrane simulations with glycolipids and lipoglycans","volume":"15","author":"Lee","year":"2019","journal-title":"J Chem Theory Comput"},{"key":"10.1124\/molpharm.122.000583_bib19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/j.1460-2075.1990.tb08264.x","article-title":"Selective binding of ligands to beta 1, beta 2 or chimeric beta 1\/beta 2-adrenergic receptors involves multiple subsites","volume":"9","author":"Marullo","year":"1990","journal-title":"EMBO J"},{"key":"10.1124\/molpharm.122.000583_bib20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41589-018-0145-x","article-title":"Structural insights into binding specificity, efficacy and bias of a \u03b22AR partial agonist","volume":"14","author":"Masureel","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1124\/molpharm.122.000583_bib21","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1124\/molpharm.122.000583_bib22","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1021\/jm400348g","article-title":"Synthesis and in vitro and in vivo characterization of highly \u03b21-selective \u03b2-adrenoceptor partial agonists","volume":"56","author":"Mistry","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.122.000583_bib23","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1124\/molpharm.122.000583_bib24","doi-asserted-by":"crossref","DOI":"10.1063\/5.0014475","article-title":"Scalable molecular dynamics on CPU and GPU architectures with NAMD","volume":"153","author":"Phillips","year":"2020","journal-title":"J Chem Phys"},{"key":"10.1124\/molpharm.122.000583_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nature06325","article-title":"Crystal structure of the human beta2 adrenergic G-protein-coupled receptor","volume":"450","author":"Rasmussen","year":"2007","journal-title":"Nature"},{"key":"10.1124\/molpharm.122.000583_bib26","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J Chem Theory Comput"},{"key":"10.1124\/molpharm.122.000583_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41586-019-1141-3","article-title":"Structural basis of ligand recognition at the human MT1 melatonin receptor","volume":"569","author":"Stauch","year":"2019","journal-title":"Nature"},{"key":"10.1124\/molpharm.122.000583_bib28","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15\u2014ligand discovery for everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1124\/molpharm.122.000583_bib29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature07101","article-title":"Structure of a \u03b21-adrenergic G-protein-coupled receptor","volume":"454","author":"Warne","year":"2008","journal-title":"Nature"},{"key":"10.1124\/molpharm.122.000583_bib30","series-title":"Current Protocols in Bioinformatics","article-title":"Comparative protein structure modeling using Modeller","author":"Webb","year":"2014"},{"key":"10.1124\/molpharm.122.000583_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(90)91517-E","article-title":"Xamoterol in severe heart failure","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"10.1124\/molpharm.122.000583_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature22035","article-title":"Structural basis for selectivity and diversity in angiotensin II receptors","volume":"544","author":"Zhang","year":"2017","journal-title":"Nature"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24012641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24012641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.122.000583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:28:37Z","timestamp":1740763717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24012641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0026895X24012641"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.122.000583","relation":{},"ISSN":["0026-895X"],"issn-type":[{"type":"print","value":"0026-895X"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human \u03b21-Adrenoceptor","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.122.000583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s)","name":"copyright","label":"Copyright"}]}}